SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 57.92 |
| Enterprise Value ($M) | 67.95 |
| Book Value ($M) | -5.79 |
| Book Value / Share | -0.03 |
| Price / Book | -10.01 |
| NCAV ($M) | -320.03 |
| NCAV / Share | -1.65 |
| Price / NCAV | -0.18 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.79 |
| Return on Assets (ROA) | -0.48 |
| Return on Equity (ROE) | -1.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.33 |
| Current Ratio | 0.51 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 150.81 |
| Assets | 465.06 |
| Liabilities | 470.84 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Granahan Investment Management Inc/ma | 0.00 | -100.00 | |
| 13G/A | Alyeska Investment Group, L.P. | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 5.40 | 0.00 | |
| 13G/A | Goldman Sachs Group Inc | 1.10 | -81.99 | |
| 13G | BlackRock, Inc. | 8.00 | 0.00 | |
| 13G/A | State Street Corp | 1.80 | -75.28 | |
| 13G/A | PFM Health Sciences, LP | 1.90 | ||
| 13G/A | Tang Capital Partners Lp | 0.90 | -63.33 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,255,508 | 10,221,747 | 41.63 | |
| 1,256,884 | 3,708,286 | 33.89 | |
| 1,244,588 | 3,279,970 | 37.95 | |
| 1,738,782 | 4,636,159 | 37.50 | |
| 1,241,766 | 3,423,470 | 36.27 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BDTX – Black Diamond Therapeutics, Inc. | BEAM – Beam Therapeutics Inc. |
| BIIB – Biogen Inc. | BMEA – Biomea Fusion, Inc. |
| BMRN – BioMarin Pharmaceutical Inc. |
Financial data and stock pages provided by
Fintel.io